New application note with PerkinElmer: High content analysis with InSphero’s 3D microtissues With this high content screening application you can analyze different characteristics of 3D microtissues using the Operetta® High Content Imaging System. View application note.
Last chance to register: Workshop on 3D cell culture in Manchester on Sep 7 Register today to meet experts on 3D cell culture and in vitro toxicology at our half-day workshop. The speaker panel includes James Sidaway (AstraZeneca) and Philip Hargreaves (Promega) View the program here or register by e-mail now!
*50% discount for ELRIG Drug Discovery 2012 participants* Visit the InSphero stand (G3) at Drug Discovery 2012 to request a 50% discount voucher for this workshop!
Join our US Workshops on 3D cell culture in BOS on Oct 29 & SFR on Nov 2 Our next full-day workshops in Boston and San Francisco will bring together experts on 3D cell culture and drug discovery from academia and industry. Reserve the date today and request more information here!
InSphero joins Oncotyrol – world-leading Austrian consortium for novel anticancer treatments InSphero is partnering with Oncotyrol to foster the development of personalized anti-cancer treatments based on InSphero’s tumor microtissue models. Read more here.
3D cell culture literature picks – Aug 2012 Our applications team has reviewed a small selection of current 3D-cell-culture journal papers to keep you updated about recent developments in 3D.
InSphero is a leading supplier of organotypic, biological in-vitro 3D microtissues for highly predictive drug testing. The company, headquartered in Zurich, Switzerland, currently counts 6 of the top ten global pharmaceutical and cosmetics companies as customers, and is helping them implement the company’s patent-pending microtissue technology in their development work-flow. InSphero’s 3D microtissues are scaffold free, highly reproducible and delivered in an automation-compatible 96-well format to replace conventional 2D cell assays for better biological relevance and predictivity. The 3D cancer microtissues reflect tumor physiology and are used routinely for screening. For toxicology and metabolics applications, rat and human 3D liver microtissues predict even rare cases of idiosyncratic toxicology and remain viable for more than 5 weeks for chronic studies. InSphero’s off-the-shelf portfolio of assay-ready microtissues is complemented by custom-made 3D microtissues with a development time of 4-6 weeks and production turnaround of less than 10 days.
InSphero is a spin-off company of the Swiss Federal Institute of Technology (ETH) Zurich and the University Zurich. The company was recognized for its scientific and commercial achievements with a number of awards, including the VentureKick award, Heuberger Entrepreneurial Award, CTIstartup certification and the SLAS New Product Award (NPA) 2011 Designation. InSphero is also officially certified to the ISO 9001:2008 standard for its Quality Management System.